10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001193125-18-045737.txt : 20180214 0001193125-18-045737.hdr.sgml : 20180214 20180214165530 ACCESSION NUMBER: 0001193125-18-045737 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180214 DATE AS OF CHANGE: 20180214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 18613104 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d502472d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter during the preceding 12 months (of for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of Common Shares, without par value, outstanding as of February 14, 2018 was 7,416,814.

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	December 31, 2017 (unaudited)			June 30, 2017
ASSETS
Current Assets:
Cash and cash equivalents	$	2,959		$	10,494
Restricted cash		0			1,000
Receivables - net		6,360			5,906
Inventory		2,149			2,159
Prepaid expense and other assets		4,058			3,062

Total current assets		15,526			22,621

Property, plant and equipment, at cost		29,673			28,609
Less accumulated depreciation		19,124			18,319

Property, plant and equipment - net		10,549			10,290

Noncurrent Assets:
Intangible assets - net		1,529			1,587
Income taxes receivable		296			0
Other noncurrent assets		758			838

Total noncurrent assets		2,583			2,425

TOTAL ASSETS	$	28,658		$	35,336

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,765		$	1,571
Current maturities of long-term debt, net of debt issuance costs		263			6,710
Accrued payroll and related taxes		1,932			2,098
Due to third party payors		307			658
Other accrued expenses		1,171			1,277

Total current liabilities		5,438			12,314
Long-Term Liabilities
Long-term debt, net of debt issuance costs		2,929			0
Noncurrent liability for professional liability risks		829			1,040
Other noncurrent liabilities		258			289

Total long-term liabilities		4,016			1,329

Commitment and Contingencies

Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 7,417 shares at December 31, 2017 and 9,163 at June 30, 2017		3,708			4,581
Additional paid-in capital		11,038			13,103
Retained earnings		4,785			4,336
Accumulated other comprehensive loss		(327	)		(327	)

Total Shareholders’ Equity		19,204			21,693

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	28,658		$	35,336

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(unaudited)


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Operating revenues (net of contractual allowances)	$	14,038		$	14,359		$	27,471		$	27,438
Less provision for bad debts of Healthcare Facilities segment		160			104			230			137

Net revenues		13,878			14,255			27,241			27,301
Costs and Expenses
Cost of goods sold		5,092			5,433			9,550			10,069
Salaries, wages and benefits		5,888			5,759			11,652			11,604
Provision for bad debts of Pharmacy segment		88			125			208			216
Supplies		488			482			913			918
Purchased services		662			713			1,349			1,421
Other operating expenses		1,145			1,111			2,587			2,821
Rent and lease expense		160			138			314			267
EHR incentive payments		(4	)		0			(21	)		0
Depreciation and amortization		439			466			868			910

Operating Profit (Loss)		(80	)		28			(179	)		(925	)
Other Income (Expense):
Gain (Loss) on sale of assets		(4	)		2,995			(2	)		3,017
Gain on economic damages claim, net		944			0			944			0
Loss on extinguishment of debt		(238	)		(289	)		(238	)		(243	)
Interest expense net		(119	)		(157	)		(246	)		(378	)

Earnings from Continuing Operations before income taxes		503			2,577			279			1,471
Income Tax Benefit		(296	)		(372	)		(296	)		(228	)

Earnings from Continuing Operations		799			2,949			575			1,699
Earnings (Loss) from Discontinued Operations, net of tax		(73	)		149			(126	)		4,422

Net Earnings		726			3,098			449			6,121
Other comprehensive income		0			0			0			0

Comprehensive Earnings	$	726		$	3,098		$	449		$	6,121

Earnings (Loss) Per Share:
Continuing Operations:
Basic	$	0.09		$	0.31		$	0.06		$	0.18

Diluted	$	0.09		$	0.31		$	0.06		$	0.18

Discontinued Operations:
Basic	$	(0.01	)	$	0.02		$	(0.01	)	$	0.47

Diluted	$	(0.01	)	$	0.02		$	(0.01	)	$	0.47

Net Earnings:
Basic	$	0.08		$	0.33		$	0.05		$	0.65

Diluted	$	0.08		$	0.33		$	0.05		$	0.65

Weighted-Average Common Shares Outstanding:
Basic		8,688			9,443			9,125			9,443

Diluted		8,758			9,450			9,196			9,449


See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Six Months Ended
	December 31,
	2017			2016
Net Cash Provided by (Used in) Operating Activities	$	265		$	(3,914	)

Cash Flows Provided by (Used in) Investing Activities:

Expenditures for property, plant and equipment - continuing operations		(1,072	)		(808	)
Proceeds from sale of other assets		2			4,936
Proceeds from sale of hospital		0			14,620

Net Cash Provided by (Used in) Investing Activities		(1,070	)		18,748

Cash Flows Used in Financing Activities:
Payments on long-term debt - continuing operation		(3,784	)		(3,716	)
Repurchase of common shares		(2,946	)		0

Net Cash Used in Financing Activities		(6,730	)		(3,716	)

Net increase (decrease) in Cash and Cash Equivalents		(7,535	)		11,118

Cash and Cash Equivalents Beginning of Period		10,494			3,261

Cash and Cash Equivalents End of Period	$	2,959		$	14,379

Supplemental Disclosure of Cash Flow Information:

Cash Paid for:
Interest	$	218		$	206

Income taxes	$	0		$	33


See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND SIX MONTHS ENDED DECEMBER 31, 2017

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2017 and for the three and six month periods ended December 31, 2017 and 2016 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2017 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on September 28, 2017. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84-bed community hospital and a 66-bed nursing home in Mississippi, a 100-bed nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines.

The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets.

The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines.

On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $188 will be reported in results for the three months ended March 31, 2018.

Throughout these notes to the consolidated financial statements, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended December 31,						Six Months Ended December 31,
	2017			2016			2017			2016
Net Revenues:
Chestatee Hospital	$	0		$	268		$	0		$	2,369
Other Sold Hospitals		6			14			(6	)		(220	)

	$	6		$	282		$	(6	)	$	2,149

Earnings (Loss) before income taxes:
Chestatee Hospital	$	(37	)	$	251		$	(38	)	$	187
Other Sold Hospitals		0			3			(16	)		(235	)
Life sciences and engineering		(36	)		(38	)		(72	)		(75	)
Gain on sale of Chestatee Hospital		0			24			0			7,270

Earnings (Loss) before income taxes		(73	)		240			(126	)		7,147

Income tax expense		0			91			0			2,725

Earnings (Loss) from discontinued operations	$	(73	)	$	149		$	(126	)	$	4,422

Chestatee Hospital—On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. The purchase price adjustment due to the Company from the hospital buyer of $339 is currently in mediation. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds were used for the repayment of debt.

Other Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicaid cost report settlements.

Life Sciences and Engineering Segment—SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and six months ended December 31, 2017 and 2016.

The components of pension expense for the three and six months ended December 31, 2017 and 2016, respectively, were as follows:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Interest Cost	$	14		$	13		$	28		$	26
Expected return on assets		(9	)		(8	)		(18	)		(16	)
Amortization of prior service cost		31			33			62			65

Net pension expense	$	36		$	38		$	72		$	75

SunLink contributed $70 to the plan in the six months ended December 31, 2017 and expects to contribute an additional $70 during the last two fiscal quarters of the fiscal year ending June 30, 2018.

Note 4. – Economic Damages Claim

The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the three and six months ended December 31, 2017 and as of December 31, 2017, the net settlements of $944 are included in Prepaid expense and other assets on the December 31, 2017 Condensed Consolidated Balance Sheets.

Note 5. – Restricted Cash

Under the Fourth Amendment to the Trace RDA Loan dated January 7, 2017 (see Note 9. Long-Term Debt) a deposit of $1,000 in a blocked interest bearing account was held by the lender. Under the Fifth Amendment to the Trace RDA Loan dated December 26, 2017, the blocked account was eliminated and a prepayment was made on the Trace RDA loan.

Note 6. – Shareholders’ Equity

Common Share Purchase Tender Offer – On November 21, 2017, SunLink commenced a tender offer for the purchase of a portion of its common shares at a price of $1.60 per share (the “Offer”). The offer expired on December 21, 2017 with 3,725,656 common shares tendered. In accordance with the terms and conditions of the Offer, the Company accepted for payment a total of approximately 1,745,751 shares at a price of $1.60 per share for a total cost of approximately $2,793, excluding fees and expenses relating to the Offer.

Stock-Based Compensation – For the three months ended December 31, 2017 and 2016, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2017 and 2016, the Company recognized $6 and $54, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 0 and 72,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2017 and 2016, respectively.

Note 7. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues by payor were as follows for the three and six months ended December 31, 2017 and 2016:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Healthcare Facilities Segment:
Medicare	$	2,386		$	2,335		$	4,682		$	4,368
Medicaid		2,102			2,404			4,237			4,900
Self-pay		269			151			441			270
Managed Care & Other Insurance		771			657			1,485			1,377
Other		354			405			761			775

Revenues before provision for doubtful accounts		5,882			5,952			11,606			11,690
Provision for doubtful accounts		(160	)		(104	)		(230	)		(137	)

Healthcare Facilities Segment Net Revenues		5,722			5,848			11,376			11,553
Pharmacy Segment Net Revenues		8,156			8,407			15,865			15,748

Total Net Revenues	$	13,878		$	14,255		$	27,241		$	27,301

The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:


	December 31,			June 30,
	2017			2017
Accounts receivable (net of contractual allowances)	$	6,905		$	6,458
Less allowance for doubtful accounts		(545	)		(552	)

Patient accounts receivable - net	$	6,360		$	5,906

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Services Segment and the Pharmacy Segment for the three and six months ended December 31, 2017 and 2016:


	Healthcare
	Services			Pharmacy			Total
Three Months Ended December 31, 2017
Balance at October 1, 2017	$	308		$	192		$	500
Additions recognized as a reduction to revenues:
Continuing Operations		160			88			248
Discontinued Operations		(6	)		0			(6	)
Accounts written off, net of recoveries		(136	)		(61	)		(197	)

Balance at December 31, 2017	$	326		$	219		$	545


	Healthcare
	Services			Pharmacy			Total
Six Months Ended December 31, 2017
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		230			208			438
Discontinued Operations		6			0			6
Accounts written off, net of recoveries		(238	)		(213	)		(451	)

Balance at December 31, 2017	$	326		$	219		$	545


	Healthcare
	Services			Pharmacy			Total
Three Months Ended December 31, 2016
Balance at October 1, 2016	$	402		$	390		$	792
Additions recognized as a reduction to revenues:
Continuing Operations		104			125			229
Discontinued Operations		(15	)		0			(15	)
Accounts written off, net of recoveries		(159	)		(115	)		(274	)

Balance at December 31, 2016	$	332		$	400		$	732


	Healthcare
	Services			Pharmacy			Total
Six Months Ended December 31, 2016
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		137			216			353
Discontinued Operations		392			0			392
Accounts written off, net of recoveries		(821	)		(183	)		(1,004	)

Balance at December 31, 2016	$	332		$	400		$	732

Note 8. – Intangible Assets

Intangibles consist of the following, net of amortization:


	December 31			June 30,
	2017			2017
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,363	)		(1,305	)

Net Intangibles	$	1,529		$	1,587

Amortization expense was $29 and $35 for the three months ended December 31, 2017 and 2016, respectively. Amortization expense was $58 and $71 for the six months ended December 31, 2017 and 2016, respectively.

Note 9. –Long-Term Debt

Long-term debt consisted of the following:


	December,			June 30,
	2017			2017
Trace RDA Loan	$	3,417		$	7,191
Capital lease obligations and other		2			12

Total		3,419			7,203
Less unamortized debt issuance costs		(227	)		(493	)
Less current maturities		(263	)		(6,710	)

Long-term Debt	$	2,929		$	0

Trace RDA Loan—Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal payments on the RDA Loan were reduced to $39 per month, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (5.5% at December 31, 2017) and certain loan covenants were modified. The Modification also included a waiver of covenant violations for the quarters ended June 30 and September 30, 2017. Trace was in compliance with the amended financial covenants at December 31, 2017. In connection with the modification and prepayment, an existing deposit of $1,000 in a blocked, interest bearing account with the lender was released. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

Note 10. – Income Taxes

Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $372 ($399 federal tax benefit and $27 state tax expense) was recorded for continuing operations for the three months ended December 31, 2017 and 2016, respectively. Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $228 ($189 federal tax benefit and $39 state tax benefit) was recorded for continuing operations for the six months ended December 31, 2017 and 2016, respectively.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB”) on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available.

At December 31, 2017, consistent with the above processes, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that only our federal alternative minimum tax (“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $7,921 against all other net deferred tax asset items at December 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

The principal negative evidence that led us to determine at December 31, 2017 that $7,921of the net deferred tax assets resulting from non-AMT credit carryforwards should have full valuation allowances was the three-year cumulative pre-tax loss as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate.

For Federal income tax purposes, at December 31, 2017, the Company had approximately $12,700 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025. With the enactment of TCJA, Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date.

Note 11. – Commitments and Contingencies

Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2017 were as follows:


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	263	$	554	$	168
2 years		300		349		152
3 years		317		293		133
4 years		336		111		113
5+ years		2,203		13		244

	$	3,419	$	1,320	$	810

On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH”) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements; however the nursing home anticipates further surveys to evaluate its implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the six months ended December 31, 2017. The CMP was paid January 18, 2018.

Note 12. - Related Party Transactions

A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $125 and $175 for legal services to this law firm in the three months ended December 31, 2017 and 2016, respectively. The Company expensed an aggregate of $190 and $372 for legal services to this law firm in the six months ended December 31, 2017 and 2016, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2017 and June 30, 2017 is $116 and $38, respectively, of amounts payable to this law firm.

Note 13. - Subsequent Event

Note 14. - Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of December 31, 2017 and 2016 and for the three and six months then ended is as follows:


	Healthcare					Corporate
	Facilities		Pharmacy			and Other			Total
As of and for the three months ended December 31, 2017
Net revenues from external customers	$	5,722	$	8,156		$	0		$	13,878
Operating profit (loss)		61		229			(370	)		(80	)
Depreciation and amortization		160		278			1			439
Assets		14,348		10,752			3,558			28,658
Expenditures for property, plant and equipment		337		51			0			388

As of and for the three months ended December 31, 2016
Net revenues from external customers	$	5,848	$	8,407		$	0		$	14,255
Operating profit (loss)		424		5			(401	)		28
Depreciation and amortization		198		267			1			466
Assets		13,859		12,022			14,762			40,643
Expenditures for property, plant and equipment		167		397			0			564

As of and for the six months ended December 31, 2017
Net revenues from external customers	$	11,376	$	15,865		$	0		$	27,241
Operating profit (loss)		4		652			(835	)		(179	)
Depreciation and amortization		318		548			2			868
Assets		14,348		10,752			3,558			28,658
Expenditures for property, plant and equipment		813		259			0			1,072

As of and for the six months ended December 31, 2016
Net revenues from external customers	$	11,553	$	15,748		$	0		$	27,301
Operating profit (loss)		292		(187	)		(1,030	)		(925	)
Depreciation and amortization		387		521			2			910
Assets		13,859		12,022			14,762			40,643
Expenditures for property, plant and equipment		222		586			0			808

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and co-insurance, or other terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home, and pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions, and capital improvements at existing healthcare and pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and

•

fluctuations in the market value of equity securities including SunLink common shares.

Operational Factors

•

ability or inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists, and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

changes in interest rates under lending agreements and other indebtedness;

•

the ability or inability to refinance existing indebtedness and existing or potential defaults under existing indebtedness;

•

restrictions imposed by existing or future lending agreements or other indebtedness;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general liability insurance;

•

the efforts of insurers, healthcare providers, and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

risks of changes in estimates of self-insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Services and Pharmacy segments;

•

changes in wages as a result of inflation or competition for physician, nursing, pharmacy, management and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality of or costs with respect to our information systems for our Healthcare Services and Pharmacy segments and our corporate office, including both software and hardware;

•

the availability of and competition from alternative drugs or treatments to those provided by our Pharmacy segment; and

•

the restrictions, processes, and conditions relating to our Pharmacy segment imposed by pharmacy benefit providers, drug manufacturers, and distributors.

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees, disposition agreements, and other obligations relating to discontinued operations, including claims from sold or leased Facilities, retained liabilities or retained subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general, and other claims which may be asserted against us; and

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage, and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules on reimbursement terms;

•

the decision by states in which we operate our remaining hospital (Mississippi) and two remaining nursing homes (Georgia and Mississippi) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations affecting our Healthcare Services and Pharmacy Segments; and

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy Facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding and other reforms).

Dispositions, Acquisition and Renovation Related Matters

•

the ability to dispose of underperforming Facilities and business segments;

•

the availability and terms of capital to fund acquisitions, improvements, renovations or replacement Facilities; and

•

competition in the market for acquisitions of hospitals, nursing homes, pharmacy Facilities, and healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. We disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based, except as required by applicable law. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the other risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions, will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

•

changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2017 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims; and

•

Accounting for income taxes

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Services and Pharmacy.


	Three Months Ended									Six Months Ended
	December 31,									December 31,
	2017			2016			% Change			2017			2016			% Change
Net Revenues - Healthcare Services	$	5,722		$	5,848			-2.2	%	$	11,376		$	11,553			-1.5	%
Net Revenues - Pharmacy		8,156			8,407			-3.0	%		15,865			15,748			0.7	%

Total Net Revenues		13,878			14,255			-2.6	%		27,241			27,301			-0.2	%
Costs and expenses		(13,958	)		(14,227	)		-1.9	%		(27,420	)		(28,226	)		-2.9	%

Operating profit (loss)		(80	)		28			NA			(179	)		(925	)		NA
Interest expense - net		(119	)		(157	)		-24.2	%		(246	)		(378	)		-34.9	%
Loss on extinguishment of debt		(238	)		(289	)		-17.6	%		(238	)		(243	)		-2.1	%
Gain on economic damages claim, net		944			0			NA			944			0			NA
Gain (Loss) on sale of assets		(4	)		2,995			-100.1	%		(2	)		3,017			-100.1	%

Earnings from continuing operations before income taxes	$	503		$	2,577			-80.5	%	$	279		$	1,471			-81.0	%

Healthcare Facilities Segment:
Hospital and Nursing Home Admissions		156			124			25.8	%		322			245			31.4	%
Hospital and Nursing Patient Days		14,128			15,273			-7.5	%		28,873			30,707			-6.0	%

Results of Operations

Healthcare Services Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Services segment for the periods indicated:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Source:
Medicare		40.6	%		39.2	%		40.3	%		37.4	%
Medicaid		35.7	%		40.4	%		36.5	%		41.9	%
Managed Care Insurance & Other		19.1	%		17.9	%		19.4	%		18.4	%
Self-pay		4.6	%		2.5	%		3.8	%		2.3	%

		100.0	%		100.0	%		100.0	%		100.0	%

The Healthcare Services segment in the current year is composed of two nursing homes, one hospital, a subsidiary which provides information technology (“IT”) services to outside customers and SunLink subsidiaries, two leased medical office buildings, and unimproved land at three locations. Healthcare Services net revenues decreased $126, or 2%, for the three months ended December 31, 2017 compared to the prior year period. Decreased nursing home Medicaid revenues, partially offset by increased physician clinic and nursing home Medicare revenues, resulted in the decreased net revenues. Healthcare Services net revenues decreased $177, or 1%, for the six months ended December 31, 2017 compared to the prior year period. Decreased nursing home Medicaid revenues, partially offset by increased physician clinic and nursing home Medicare revenues, resulted in the decreased net revenues. There were $264 prior years’ Medicare positive cost report settlements for the three and six months ended December 31, 2017 and $347 for the three and six months ended December 31, 2016.

Pharmacy Segment Net Revenues

Pharmacy segment net revenues for the three months ended December 31, 2017 decreased $251, or 3%, from the three months ended December 31, 2016. The decrease was a result of an 8% decrease in Durable Medical Equipment (“DME”) net revenues offset by a 2% increase in Retail Pharmacy net revenues. Pharmacy segment net revenues for the six months ended December 31, 2017 increased $117, or 1%, from the six months ended December 31, 2016. The increase was a result of a 6% increase in Durable Medical Equipment (“DME”) net revenues partially offset by a 1% decrease in Retail Pharmacy net revenues and a 1% decrease in Institutional Pharmacy net revenues. DME net revenues increased primarily due to increased Medicare reimbursement realized from the implementation of the provisions of the 21^st Century Cures Act. The Company expects that the increased revenues from the 21^st Century Cures Act will not continue in material amounts this fiscal year. The average net revenue per Retail Pharmacy sales order decreased 5% in the current year despite a 5% increase in script volume due to decreased reimbursement from government and insurance insurances. Institutional Pharmacy script volume decreased 5% in the current year.

Healthcare Services Segment Cost and Expenses

Costs and expenses for our Healthcare Services Segment, including depreciation and amortization, were $5,661 and $5,424 for the three months ended December 31, 2017 and 2016, respectively. Costs and expenses for our Healthcare Services segment, including depreciation and amortization, were $11,372 and $11,261 for the six months ended December 31, 2017 and 2016, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Salaries, wages and benefits		68.5	%		63.8	%		68.0	%		63.9	%
Supplies		8.0	%		8.9	%		7.5	%		8.8	%
Purchased services		6.7	%		4.8	%		6.7	%		5.5	%
Other operating expenses		11.9	%		11.5	%		14.1	%		15.2	%
Rent and lease expense		1.0	%		0.6	%		1.0	%		0.7	%
Depreciation and amortization expense		2.8	%		3.2	%		2.8	%		3.4	%

Salaries, wages and benefits increased as a percent of net revenue for the three and six months ended December 31, 2017 due to increased employee medical claims when compared to same period last year. Supplies and Other operating expenses decreased this year because last year’s expenses included expenses related to a hospital that ceased operations in June 2016. Purchased services expense increased for the three and six months ended December 31, 2017, as compared to the same period last year due to increased legal expenses. Depreciation and amortization expense decreased $37 and $68 for the three and six months ended December 31, 2017, as compared to the same period last year as a result of the sale of a medical office building last year.

Pharmacy Segment Cost and Expenses

Cost and expenses for our Pharmacy segment, including depreciation and amortization, were $7,927 and $8,402 for the three months ended December 31, 2017 and 2016, respectively. Cost and expenses for our Pharmacy segment, including depreciation and amortization, were $15,213 and $15,935 for the six months ended December 31, 2017 and 2016, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Cost of goods sold		62.4	%		64.6	%		60.2	%		63.9	%
Salaries, wages and benefits		21.8	%		22.4	%		22.1	%		23.8	%
Provision for bad debts		1.1	%		1.5	%		1.3	%		1.4	%
Supplies		0.4	%		0.4	%		0.4	%		0.4	%
Purchased services		3.3	%		3.5	%		3.5	%		3.8	%
Other operating expenses		3.7	%		3.4	%		3.0	%		3.6	%
Rent and lease expense		1.1	%		0.9	%		1.0	%		1.0	%
Depreciation and amortization expense		3.4	%		3.2	%		3.5	%		3.3	%

Cost of goods sold as a percent of net revenues decreased in the three and six month period ended December 31, 2017 as compared to the comparable period of the prior year due to changes in sales product mix and increased discounts from their venders. Salaries, wages and benefits as a percent of net revenues decreased in the three and six month period ended December 31, 2017 as compared to the comparable period of the prior year due to a reduction in labor force which began last fiscal year. Provision for bad debts decreased for the three months ended December 31, 2017 as compared to last year due to the decrease in DME net revenues.

Operating Profit and Loss

The Company reported an operating loss of $80 for the three months ended December 31, 2017 compared to operating profit of $28 for the three months ended December 31, 2016. The operating loss for the three months ended December 31, 2017 compared to the operating profit for the prior year’s three month period resulted from the 3% decrease in net revenues.

The Company reported an operating loss of $179 for the six months ended December 31, 2017 compared to operating loss of $925 for the six months ended December 31, 2016. The operating loss last year included expenses related to a hospital that ceased operations in June 2016.

Gain on economic damages claim

Interest Expense

Interest expense was $119 and $157 for the three months ended December 31, 2017 and 2016, and $246 and $378 for the six months ended December 31, 2017 and 2016, respectively. The decrease in interest expense resulted from lower debt outstanding in the current fiscal year, primarily because as debt was reduced $3,985 last fiscal year with no additional debt undertaken.

Income Taxes

(“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $7,921 against all other net deferred tax asset items at December 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

For Federal income tax purposes, at December 31, 2017, the Company had approximately $12,700 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025, With the enactment of TCJA; Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date.

Gain on Sale of Assets

In December 2016, a subsidiary sold a medical office building complex, comprised of land and three buildings in Ellijay, GA (“Ellijay MOB”) for $4,900. A gain of $2,819 was reported on the sale.

Earnings (Loss) from Continuing Operations before Income Tax

Earnings from continuing operations before income tax was $503 for the three months ended December 31, 2017 compared to earnings from continuing operations before income tax of $2,577 for the three months ended December 31, 2016. Earnings from continuing operations before income tax was $279 for the six months ended December 31, 2017 compared to earnings from continuing operations before income tax of $1,471 for the six months ended December 31, 2016. The decreased earnings from continuing operations this year results from the non-recurrence of the gain on the sale of assets last year.

Earnings (Loss) After Taxes

Earnings from continuing operations were $799 (or $0.09 per fully diluted share) for the three months ended December 31, 2017 compared to earnings from continuing operations of $2,949 (or $0.31 per fully diluted share) for the three months ended December 31, 2016. Earnings from continuing operations were $575 (or $0.06 per fully diluted share) for the six months ended December 31, 2017 compared to earnings from continuing operations of $1,699 (or $0.18 per fully diluted share) for the six months ended December 31, 2016.

Net earnings for the three months ended December 31, 2017 was $726 (or $0.08 fully diluted share) compared to net earnings of $3,098 ($0.32 earnings per fully diluted share) for the three months ended December 31, 2016. Net earnings for the six months ended December 31, 2017 was $449 (or $0.05 fully diluted share) compared to net earnings of $6,121 ($0.65 earnings per fully diluted share) for the six months ended December 31, 2016. Net earnings last year included $4,422 of earnings from discontinued operations which resulted from the gain on the sale of a hospital in August 2016.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges, we refer to such measurement as “Adjusted EBITDA”, which we report on a Company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Services segment Adjusted EBITDA and Pharmacy segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three and six months ended December 31, 2017 and 2016, respectively, is shown below.


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Healthcare Services Adjusted EBITDA	$	221		$	622		$	322		$	679
Pharmacy Adjusted EBITDA		507			272			1,200			334
Corporate overhead costs		(369	)		(400	)		(833	)		(1,028	)
Taxes and interest expense		177			215			50			(150	)
Other non-cash expenses and net change in operating assets and liabilities		(504	)		(1,433	)		(474	)		(3,749	)

Net cash provided by (used in) operations	$	32		$	(724	)	$	265		$	(3,914	)

Liquidity and Capital Resources

Overview

Our primary source of liquidity is unrestricted cash on hand of $2,959 at December 31, 2017. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We nevertheless periodically seek options to obtain financing for the liquidity needs of the Company or individual subsidiaries. The Company and its subsidiaries currently are funding working capital needs primarily from cash on hand and from the sale of assets. See “Subsidiary Loans” below.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	263	$	554	$	168
2 years		300		349		152
3 years		317		293		133
4 years		336		111		113
5+ years		2,203		13		244

	$	3,419	$	1,320	$	810

At December 31, 2017, we had outstanding long-term debt of $3,419 of which $3,417 was incurred under the Trace RDA Loan and $2 was related to other debt.

On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH“) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements; however the nursing home anticipates further surveys to evaluate its implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the six months ended December 31, 2017. The CMP was paid January 18, 2018.

Discontinued Operations

Chestatee Hospital—On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,246 is subject to adjustment for various purchase price adjustments. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds were used for the repayment of debt.

Other Sold Hospitals – Subsidiaries of the Company have sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicaid cost report settlements.

Related Party Transactions

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our principal executive officer and principal financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of December 31, 2017.

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2017.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended December 31, 2017 in our internal control over financial reporting that materially affected, or is likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1.

LEGAL PROCEEDINGS

ITEM 1A.

RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2017. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6.

EXHIBITS

Exhibits:



10.1		Fifth Amendment to Loan Agreement, Modification of Note and Waiver among Southern Health Corporation of Houston, Inc., Crown Healthcare Investments, LLC, SunLink Health Systems, Inc. and Bank SNB, National Association.

31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended December 31, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of December 31, 2017 (unaudited) and June 30, 2017, (ii) Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2017 and 2016 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three and six months ended December 31, 2017 and 2016 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: February 14, 2018

EX-10.1 2 d502472dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

FIFTH AMENDMENT TO LOAN AGREEMENT, MODIFICATION OF NOTE AND WAIVER

THIS FIFTH AMENDMENT TO LOAN AGREEMENT, MODIFICATION OF NOTE AND WAIVER (this “Amendment”) is dated as of December 26, 2017 (the “Effective Date”), among Southern Health Corporation of Houston, Inc., a Georgia corporation (“Borrower”), Crown Healthcare Investments, LLC, a Georgia limited liability company (f/k/a MedCare South, LLC) (“Crown”), SunLink Health Systems, Inc., an Ohio corporation (“SunLink” and, together with Crown, “Guarantors”) and Bank SNB, National Association (f/k/a Stillwater National Bank and Trust Company) (“Lender”).

PRELIMINARY STATEMENTS

A. Borrower and Lender are parties to (i) the Mortgage Loan Agreement, dated July 5, 2012 (as amended from time to time, the “Loan Agreement”) and (ii) the Promissory Note, dated July 5, 2012 (the “Note”).

B. Capitalized terms used in this Amendment have the meanings given to them in the Loan Agreement. Borrower and Guarantors are collectively referred to as the “Loan Parties.”

C. Borrower has requested that Lender amend the Loan Agreement and modify the Note as more particularly described in this Amendment.

D. Lender has agreed to such amendment and modification, subject to the satisfaction of certain conditions, all as more particularly described in this Amendment.

E. For the period ending September 30, 2017 (the “Specified Period”) Borrower failed to maintain the Debt Service Coverage Ratio, the Fixed Charge Coverage Ratio, and the Funded Debt to EBITDA Ratio required by the Loan Agreement (the “Specified Default”).

F. Lender has agreed to waive the Specified Defaults, subject to the terms and conditions of this Waiver.

G. Each of the Guarantors is party to a Guaranty Agreement, dated the date of the Loan Agreement (each, a “Guaranty Agreement”), pursuant to which such Guarantor has guaranteed the obligations of Borrower under the Loan Agreement.

H. Each of the Guarantors desires to ratify and reaffirm the Guaranty Agreement to which it is a party.

AGREEMENT

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows.

1. Amendments to Loan Agreement.

a. Amendment to Section 2.2. Subject to the other terms and conditions of this Amendment, Section 2.2 of the Loan Agreement is hereby amended by it in its entirety and replacing it as follows:

“The Mortgage Note will bear interest at the interest rate equal to the Prime Rate plus 1.0% per annum, but in no event shall the Interest Rate be less than 5.5% per annum (the “Interest Rate”). “Prime Rate” means, on any day, the per annum rate of interest most recently designated as the prime rate as published in the “Money Rates” section of The Wall Street Journal. All interest on the Mortgage Note shall be calculated for the actual number of days elapsed at a per diem charge based on a year consisting of 360 days.”

b. Amendment to Section 10.6.1. Subject to the other terms and conditions of this Amendment, Section 10.6.1 of the Loan Agreement is hereby amended by deleting the first sentence of Section 10.6.1 and replacing it as follows:

“Borrower will maintain a Debt Service Coverage Ratio of at least .45:1.00 for the periods ending December 31, 2017 and March 31, 2018, and at least 1.00:1.00 thereafter.”

c. Amendment to Section 10.6.2. Subject to the other terms and conditions of this Amendment, Section 10.6.2 of the Loan Agreement is hereby amended by deleting the first sentence of Section 10.6.2 and replacing it as follows:

“Borrower will maintain a Fixed Charge Coverage Ratio of at least .45:1.00 for the periods ending December 31, 2017 and March 31, 2018, and at least 1.00:1.00 thereafter.”

d. Amendment to 10.6.4. Subject to the other terms and conditions of this Amendment, Section 10.6.4 of the Loan Agreement is hereby amended by deleting the last sentence of Section 10.6.4 and replacing it as follows:

“Borrower will maintain a Funded Debt to EBITDA Ratio not to exceed at least 15.00:1.00 for the periods ending December 31, 2017 and March 31, 2018, and at least 6.00 to 1.00 thereafter.”

e. Amendment to 10.37.1. Subject to the other terms and conditions of this Amendment, Section 10.37.1 of the Loan Agreement is hereby amended by adding the following sentence to the end of such section:

“Notwithstanding the foregoing, for the two fiscal year periods beginning July 1, 2018, Borrower may make capital expenditures of an aggregate amount of $1,000,000.00.”

2. Amendments to Note.

a. Amendment to Interest Rate. Subject to the other terms and conditions of this Amendment, the Note is hereby amended by deleting two sentences of the third paragraph of the Note and replacing them as follows:

“The Note will bear interest at the interest rate equal to the Prime Rate plus 1.0% per annum, but in no event shall the Interest Rate be less than 5.5% per annum (the “Interest Rate”). “Prime Rate” means, on any day, the per annum rate of interest most recently designated as the prime rate as published in the “Money Rates” section of The Wall Street Journal.”

3. Waiver.

a. Waiver of Specified Defaults. Subject to the terms and conditions of this Waiver, Lender hereby waives the Specified Defaults.

b. Limitations. The foregoing waiver is a waiver solely of the Specified Defaults for the Specified Period, and is not a waiver of any future default or any provision of the Loan Agreement generally. This waiver does not create a course of dealing. Lender is under no obligation to make any future waiver of any provision of the Loan Agreement or other Loan Documents.

4. Limited Consent. Lender consents to a one-time non-cash dividend of $10,000,000 by Borrower to Sunlink, which shall be payed by reduction on a dollar-for-dollar basis of intercompany payables owed to Borrower by Sunlink. Such consent shall not be construed to waive, or consent to any default in, any provision of the Loan Agreement generally (including Section 10.29), to create a course of dealing, or otherwise to give rise to any obligation of Lender to make any similar future accommodation.

5. Additional Agreements

a. Release of Funds. On the date of this Amendment, Lender shall release to Borrower $1,000,000 deposited by Borrower into an interest bearing blocked account maintained with Lender and all proceeds thereof pursuant to the Fourth Amendment to Loan Agreement and Waiver dated January 6, 2017 for the sole purpose of making a prepayment against the outstanding balance of the Mortgage Loan, as further described in Section 6(a).

b. Amortization Reset. Commencing on the Effective Date, the monthly payment will be reset to $39,050 and from thereafter will continue to be as set forth in the Loan Agreement.

6. Conditions Precedent.

a. Prepayment. On the date of this Amendment, Borrower shall prepay the outstanding balance of the Mortgage Loan in the amount of $3,548,000 (the “Prepayment”).

b. Representations and Warranties. Each of the representations and warranties of Borrower and the Guarantors in the Loan Documents shall be true and correct as of the date of this Amendment except for any representation or warranty made as of a date certain, in which event such representation or warranty shall be true as of such date.

c. Documents. Lender shall have received (i) this Amendment, duly executed by the parties hereto, and (ii) any other document, certificate or instrument that Lender reasonably requires in connection herewith.

7. Ratification and Release.

a. Confirmation and Ratification. Borrower and Guarantors confirm and agree that each pledge, assignment, security interest, lien or other encumbrance made by Borrower and Guarantors in favor of Lender under any Loan Document is hereby ratified and confirmed in all respects. Borrower and each Guarantor each acknowledges and confirms the validity and enforceability of all Loan Documents to which it is a party. Borrower and each Guarantor represents and warrants to Lender that such party has no right of offset, defense or counterclaim to the payment or performance of the Loans or any of its other obligations under any of the Loan Documents to which it is a party.

b. Release. In consideration of the accommodations granted by Lender in this Amendment, each Borrower and Guarantor hereby forever waives, releases and discharges Lender and its successors, assigns, directors, officers, members, managers, employees, agents, attorneys and other representatives (the “Lender Parties”), and indemnifies and holds harmless Lender and the Lender Parties from, any and all claims (including, without limitation, cross-claims, counterclaims, rights of setoff and recoupment), causes of action, demands, suits, costs, expenses and damages that it now has or hereafter may have, of whatsoever nature and kind, whether known or unknown, whether now existing or hereafter arising, whether arising at law or in equity, including all actions that arise under or relate to the Loan Documents, this Amendment, any document, instrument or certificate executed in connection with the foregoing, any action or omission of Lender or any of the Lender Parties in connection with the foregoing, or any person’s rights or obligations thereunder based in whole or in part on facts, whether or not known, existing on or prior to the date of this Amendment; provided however, neither Borrower nor Guarantor waives any right to enforce the terms of the Loan Documents, this Amendment, any document, instrument or certificate executed in connection with the foregoing in accordance with its terms. Borrower acknowledges and agrees that, in so far as Borrower is aware, all actions of Lender with respect to the Loan Documents and the transactions contemplated thereby on or prior to the date of this Amendment have been in good faith and in accordance with the Loan Documents and applicable law.

8. Representations and Warranties. The Borrower and Guarantors, jointly and severally, represent and warrant to Lender as follows:

a. This Amendment is not being made or entered into with the actual intent to hinder, delay or defraud any entity or person.

b. No action or proceeding, including, without limitation, a voluntary or involuntary petition for bankruptcy, has been instituted by or against Borrower or either Guarantor.

c. Borrower and each Guarantor each has full power and authority to enter into, execute, deliver, and perform this Amendment, and the foregoing does not violate any contractual or other obligation by which such person is bound. The execution, delivery and performance of this Amendment have been authorized by all requisite organizational action of each such person.

d. This Amendment constitutes the valid and legally binding obligation of Borrower and each Guarantor, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance and other laws affecting creditors’ rights generally and to general equitable principles.

e. The representations and warranties of Borrower and each Guarantor in the Loan Agreement and the other Loan Documents are true and correct as of the date hereof, except to the extent that such representations and warranties expressly relate to an earlier date, in which case such representations and warranties were true and correct as of such date.

9. Miscellaneous.

a. Effect on Loan Documents. Except as set forth in this Amendment, the Loan Agreement and the Loan Documents shall not be deemed amended, waived or otherwise modified by this agreement and shall remain in full force and effect.

b. Fees and Expenses. Borrower shall pay, as and when billed by Lender, all fees, costs, and expenses (including, without limitation, fees and expenses for Lender’s legal counsel, and for appraisers, engineering consultants, and environmental and other consultants) paid or incurred by Lender in connection with the negotiation of this Amendment, or in connection with the actions contemplated by this Amendment.

c. Voluntary Agreement. Borrower and each Guarantor jointly and severally represent and warrant to Lender that (a) Borrower and each Guarantor has had the opportunity to be represented by legal counsel of their choice and to consult with such counsel regarding this Amendment, (b) Borrower and each Guarantor are fully aware of the terms and provisions contained herein and of their effect, and (c) Borrower and each Guarantor have voluntarily and without coercion or duress of any kind entered into this Amendment.

d. Integration. This Amendment constitutes the entire agreement concerning the subject matter hereof, and it supersedes any prior or contemporaneous oral or written representations, statements, understandings, or agreements concerning the subject matter of this Amendment.

e. Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

f. Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Oklahoma, without giving effect to the principles of conflicts of law.

g. Headings. All headings in this Amendment are for convenience only and shall not be used to interpret any term or provision of this Amendment.

h. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall constitute an original and all of which taken together shall constitute one agreement. The parties hereto agree that their electronically transmitted signatures on this Amendment shall have the same effect as manually transmitted signatures.

i. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ANY RIGHT THAT IT MAY HAVE TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER OR RELATING TO THIS AMENDMENT, ANY LOAN DOCUMENTS OR ANY AMENDMENT, INSTRUMENT, DOCUMENT, OR AGREEMENT DELIVERED OR THAT MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN), ACTIONS OF ANY OF THE PARTIES HERETO, OR ANY OTHER RELATIONSHIP EXISTING IN CONNECTION WITH THIS AMENDMENT OR ANY LOAN DOCUMENTS, AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. EACH PARTY HERETO ACKNOWLEDGES THAT IT HAS BEEN, OR HAS HAD THE OPPORTUNITY TO BE, REPRESENTED IN THE SIGNING OF THIS AMENDMENT AND IN THE MAKING OF THIS WAIVER BY INDEPENDENT LEGAL COUNSEL SELECTED OF ITS OWN FREE WILL, AND THAT IT HAS DISCUSSED THIS WAIVER WITH SUCH LEGAL COUNSEL. EACH PARTY HERETO FURTHER ACKNOWLEDGES THAT IT HAS READ AND UNDERSTANDS THE MEANING OF THIS WAIVER.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.


BORROWER:				SOUTHERN HEALTH CORPORATION OF HOUSTON, INC.

				By:
				Name:
				Title:

GUARANTORS:				CROWN HEALTHCARE INVESTMENTS, LLC

				By:
				Name:
				Title:

				SUNLINK HEALTH SYSTEMS, INC.

				By:
				Name:
				Title:

LENDER:				BANK SNB, NATIONAL ASSOCIATION

				By:
				Name:
				Title:

EX-31.1 3 d502472dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended December 31, 2017 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of December 31, 2017 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


February 14, 2018				/s/ Robert M. Thornton, Jr.
				Robert M. Thornton, Jr.
				SunLink Health Systems, Inc.
				Chief Executive Officer

EX-31.2 4 d502472dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended December 31, 2017 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


February 14, 2018				/s/ Mark J. Stockslager
				Mark J. Stockslager
				SunLink Health Systems, Inc.
				Chief Financial Officer

EX-32.1 5 d502472dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended December 31, 2017, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

February 14, 2018

EX-32.2 6 d502472dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended December 31, 2017, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Mark J. Stockslager
Chief Financial Officer

February 14, 2018

EX-101.INS 7 ssy-20171231.xml XBRL INSTANCE DOCUMENT

1.60

7416814

1.60

0.055

792000

390000

402000

732000

40643000

14379000

14762000

12022000

13859000

400000

332000

500000

192000

308000

545000

307000

15526000

19124000

11038000

1765000

6905000

-327000

28658000

2000

2959000

7417000

3708000

7921000

1932000

296000

1529000

2149000

28658000

4016000

5438000

3419000

263000

2929000

2583000

1171000

12700000

758000

258000

2000000

4058000

10549000

29673000

6360000

4785000

19204000

227000

829000

3558000

10752000

14348000

0.055

3417000

1000000

9975000

336000

300000

263000

3419000

317000

2203000

113000

152000

168000

810000

133000

244000

111000

349000

554000

1320000

293000

13000

1089000

623000

1180000

339000

70000

116000

219000

1363000

1529000

2892000

326000

991000

3261000

367000

624000

552000

658000

22621000

18319000

13103000

1571000

6458000

-327000

35336000

12000

10494000

9163000

4581000

2098000

1587000

2159000

35336000

1329000

12314000

7203000

6710000

2425000

1277000

838000

289000

2000000

3062000

10290000

28609000

5906000

1000000

4336000

21693000

493000

1040000

7191000

1089000

623000

1180000

38000

224000

1305000

1587000

2892000

328000

296000

7270000

15000000

1745751

2017-12-21

2793000

3725656

0.01

39000

Prime rate plus 1% with a floor of 5.5%

3548000

410000

0.50

54000

1004000

71000

11118000

6121000

-189000

10069000

1421000

-39000

910000

7147000

4422000

0.65

2725000

0.65

-243000

137000

3017000

1699000

0.18

0.47

33000

1471000

0.18

0.47

-228000

378000

206000

11604000

18748000

-3716000

-3914000

6121000

-925000

267000

2821000

808000

14620000

4936000

216000

3716000

27301000

918000

9449000

9443000

27438000 808000 0

2000

-1030000

521000

-187000

586000

15748000

387000

292000

222000

11553000

2149000

-235000

-220000

7270000

187000

2369000

-75000

270000 1377000 775000 4900000 4368000

16000

26000

65000

75000

72000

372000

183000

15748000

216000

821000

137000

11553000

11690000

137000

392000

353000

392000

false

6000

451000

58000

<div> Note 11. – Commitments and Contingencies Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2017 were as follows:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">263</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">554</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">168</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">300</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">349</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">152</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">317</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">293</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">111</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">113</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,203</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">244</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,419</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,320</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">810</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH”) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements; however the nursing home anticipates further surveys to evaluate its implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the six months ended December 31, 2017. The CMP was paid January 18, 2018. </div>

-7535000

449000

-296000

9550000

1349000

<div> Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2017 were as follows:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">263</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">554</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">168</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">300</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">349</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">152</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">317</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">293</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">111</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">113</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,203</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">244</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,419</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,320</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">810</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

--12-31

868000

-126000

<div> Note 3. – Discontinued Operations All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation. Results for all of the businesses included in discontinued operations are presented in the following table:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Six Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">268</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,369</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(220</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">282</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,149</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(37</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">251</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(38</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">187</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(235</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(38</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(72</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Gain on sale of Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,270</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(73</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">240</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(126</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,147</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Income tax expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,725</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(73</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">149</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(126</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,422</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Chestatee Hospital—On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. The purchase price adjustment due to the Company from the hospital buyer of $339 is currently in mediation. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds were used for the repayment of debt. Other Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicaid cost report settlements. Life Sciences and Engineering Segment—SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and six months ended December 31, 2017 and 2016. The components of pension expense for the three and six months ended December 31, 2017 and 2016, respectively, were as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">28</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(18</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">72</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">75</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> SunLink contributed $70 to the plan in the six months ended December 31, 2017 and expects to contribute an additional $70 during the last two fiscal quarters of the fiscal year ending June 30, 2018. </div>

Q2 2018 10-Q

0.05

2017-12-31

0.05

SUNLINK HEALTH SYSTEMS INC 0000096793 Smaller Reporting Company

944000

-238000

230000

-2000

575000

0.06

-0.01

<div> Note 10. – Income Taxes Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $372 ($399 federal tax benefit and $27 state tax expense) was recorded for continuing operations for the three months ended December 31, 2017 and 2016, respectively. Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $228 ($189 federal tax benefit and $39 state tax benefit) was recorded for continuing operations for the six months ended December 31, 2017 and 2016, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB”) on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available. At December 31, 2017, consistent with the above processes, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that only our federal alternative minimum tax (“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $7,921 against all other net deferred tax asset items at December 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at December 31, 2017 that $7,921of the net deferred tax assets resulting from non-AMT credit carryforwards should have full valuation allowances was the three-year cumulative pre-tax loss as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate.   For Federal income tax purposes, at December 31, 2017, the Company had approximately $12,700 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025. With the enactment of TCJA, Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date. </div>

279000

0.06

-0.01

-296000

246000

<div> Note 8. – Intangible Assets Intangibles consist of the following, net of amortization:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,363</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,305</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,529</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,587</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization expense was $29 and $35 for the three months ended December 31, 2017 and 2016, respectively. Amortization expense was $58 and $71 for the six months ended December 31, 2017 and 2016, respectively. </div>

218000

11652000

<div> Note 9. –Long-Term Debt Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,417</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,191</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,419</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,203</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(227</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(493</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(263</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,710</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Long-term Debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,929</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Trace RDA Loan—Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal payments on the RDA Loan were reduced to $39 per month, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (5.5% at December 31, 2017) and certain loan covenants were modified. The Modification also included a waiver of covenant violations for the quarters ended June 30 and September 30, 2017. Trace was in compliance with the amended financial covenants at December 31, 2017. In connection with the modification and prepayment, an existing deposit of $1,000 in a blocked, interest bearing account with the lender was released. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary. </div>

<div> Note 4. – Economic Damages Claim The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the three and six months ended December 31, 2017 and as of December 31, 2017, the net settlements of $944 are included in Prepaid expense and other assets on the December 31, 2017 Condensed Consolidated Balance Sheets. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Note 2. – Business Operations <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Business Operations <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84-bed community hospital and a 66-bed nursing home in Mississippi, a 100-bed nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $188 will be reported in results for the three months ended March 31, 2018. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Throughout these notes to the consolidated financial statements, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations. </div>

-1070000

-6730000

265000

449000

-179000

<div> Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2017 and for the three and six month periods ended December 31, 2017 and 2016 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2017 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on September 28, 2017. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

314000

2587000

2946000

1072000

2000

208000

3784000

<div> Note 12. - Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $125 and $175 for legal services to this law firm in the three months ended December 31, 2017 and 2016, respectively. The Company expensed an aggregate of $190 and $372 for legal services to this law firm in the six months ended December 31, 2017 and 2016, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2017 and June 30, 2017 is $116 and $38, respectively, of amounts payable to this law firm. </div>

<div> Note 5. – Restricted Cash Under the Fourth Amendment to the Trace RDA Loan dated January 7, 2017 (see Note 9. Long-Term Debt) a deposit of $1,000 in a blocked interest bearing account was held by the lender. Under the Fifth Amendment to the Trace RDA Loan dated December 26, 2017, the blocked account was eliminated and a prepayment was made on the Trace RDA loan. </div>

<div> Revenues by payor were as follows for the three and six months ended December 31, 2017 and 2016:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,386</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,335</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,682</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,368</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,102</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,404</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,237</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,900</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">269</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">151</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">441</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">270</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">771</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">657</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,485</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,377</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">354</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">405</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">761</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,882</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,952</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,606</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,690</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(160</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(104</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(230</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(137</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,722</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,848</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,376</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,553</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,156</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,407</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,865</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,748</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,878</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,255</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,241</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,301</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

27241000

<div> Summary information for accounts receivable is as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,905</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,458</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(545</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(552</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,360</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,906</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Results for all of the businesses included in discontinued operations are presented in the following table:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Six Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">268</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,369</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(220</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">282</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,149</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(37</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">251</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(38</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">187</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(235</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(38</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(72</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Gain on sale of Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,270</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(73</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">240</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(126</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,147</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Income tax expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,725</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(73</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">149</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(126</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,422</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of December 31, 2017 and 2016 and for the three and six months then ended is as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,722</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,156</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,878</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(370</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(80</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">160</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">278</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">439</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,348</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,752</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,558</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,658</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">388</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,848</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,407</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,255</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">424</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(401</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">198</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">267</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,859</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,022</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,762</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,643</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">397</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">564</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the six months ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,376</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,865</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,241</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">652</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(835</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(179</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">318</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">548</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">868</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,348</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,752</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,558</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,658</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">813</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">259</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,072</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the six months ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,553</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,748</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,301</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">292</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(187</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,030</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(925</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">387</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">521</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">910</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,859</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,022</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,762</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,643</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">586</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">808</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div>

<div> Note 14. - Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy.   We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of December 31, 2017 and 2016 and for the three and six months then ended is as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,722</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,156</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,878</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(370</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(80</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">160</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">278</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">439</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,348</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,752</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,558</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,658</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">388</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,848</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,407</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,255</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">424</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(401</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">198</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">267</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,859</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,022</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,762</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,643</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">397</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">564</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the six months ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,376</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,865</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,241</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">652</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(835</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(179</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">318</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">548</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">868</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,348</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,752</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,558</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,658</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">813</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">259</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,072</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the six months ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,553</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,748</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,301</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">292</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(187</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,030</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(925</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">387</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">521</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">910</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,859</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,022</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,762</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,643</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">586</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">808</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div>

<div> Note 6. – Shareholders’ Equity Common Share Purchase Tender Offer – On November 21, 2017, SunLink commenced a tender offer for the purchase of a portion of its common shares at a price of $1.60 per share (the “Offer”). The offer expired on December 21, 2017 with 3,725,656 common shares tendered. In accordance with the terms and conditions of the Offer, the Company accepted for payment a total of approximately 1,745,751 shares at a price of $1.60 per share for a total cost of approximately $2,793, excluding fees and expenses relating to the Offer. Stock-Based Compensation – For the three months ended December 31, 2017 and 2016, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2017 and 2016, the Company recognized $6 and $54, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 0 and 72,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2017 and 2016, respectively. </div>

913000

<div> Note 13. - Subsequent Event On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $188 will be reported in results for the three months ended March 31, 2018. </div>

SSY

9196000

9125000

27471000 1072000 21000 2025 <div> The components of pension expense for the three and six months ended December 31, 2017 and 2016, respectively, were as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">28</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(18</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">72</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">75</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,363</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,305</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,529</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,587</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Services Segment and the Pharmacy Segment for the three and six months ended December 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at October 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">308</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">192</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">248</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(136</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Six Months Ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">552</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">230</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">208</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">438</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(238</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(451</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at October 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">402</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">390</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">792</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">125</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(159</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(115</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(274</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Six Months Ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">353</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">392</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">392</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(821</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(183</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,004</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Note 7. – Revenue Recognition and Accounts Receivables The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.   Revenues by payor were as follows for the three and six months ended December 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,386</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,335</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,682</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,368</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,102</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,404</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,237</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,900</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">269</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">441</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">270</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">771</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,485</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,377</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">354</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">405</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">761</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,882</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,952</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,606</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,690</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(160</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(230</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(137</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,722</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,848</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,376</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,553</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,156</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,407</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,865</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,748</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,878</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,255</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,241</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,301</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,905</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,458</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(545</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(552</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,360</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,906</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Services Segment and the Pharmacy Segment for the three and six months ended December 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at October 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">308</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">192</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">248</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(136</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Six Months Ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">552</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">230</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">208</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">438</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(238</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(451</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at October 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">402</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">390</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">792</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">125</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(159</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(115</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(274</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Services</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Six Months Ended December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">353</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">392</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">392</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(821</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(183</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,004</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Long-term debt consisted of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,417</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,419</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,203</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(227</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(493</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(263</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,710</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Long-term Debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,929</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 170000

2000

-835000

548000

652000

259000

15865000

318000

4000

813000

11376000

P15Y

2012-07-05

-6000

-16000

-6000

-38000

-72000

441000 1485000 761000 4237000 4682000

18000

28000

62000

72000

70000

84 100 66

190000

213000

944000

15865000

208000

238000

230000

11376000

11606000

230000

6000

438000

6000

1.00

188000

5000

274000

35000

3098000

-399000

5433000

713000

27000

466000

240000

149000

0.33

91000

0.33

-289000

104000

2995000

2949000

0.31

0.02

2577000

0.31

0.02

-372000

157000

5759000

3098000

28000

138000

1111000

564000

125000

14255000

482000

9450000

9443000

14359000 0

1000

-401000

267000

5000

397000

8407000

198000

424000

167000

5848000

282000

3000

14000

24000

251000

268000

-38000

151000 657000 405000 2404000 2335000

8000

13000

33000

38000

175000

115000

8407000

125000

159000

104000

5848000

5952000

104000

-15000

229000

-15000

1000

197000

29000

726000

-296000

5092000

662000

439000

-73000

0.08

944000

-238000

160000

-4000

799000

0.09

-0.01

503000

0.09

-0.01

-296000

119000

5888000

726000

-80000

160000

1145000

388000

88000

13878000

488000

8758000

8688000

14038000 4000

1000

-370000

278000

229000

51000

8156000

160000

61000

337000

5722000

6000

-37000

-36000

269000 771000 354000 2102000 2386000

9000

14000

31000

36000

125000

61000

944000

8156000

88000

136000

160000

5722000

5882000

160000

-6000

248000

-6000

0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2017-10-01 2017-12-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2017-10-01 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-10-01 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-10-01 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-10-01 2017-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-10-01 2017-12-31 0000096793 ssy:PharmacySegmentMember 2017-10-01 2017-12-31 0000096793 us-gaap:ManagementMember 2017-10-01 2017-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-10-01 2017-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2017-10-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2017-10-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2017-10-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2017-10-01 2017-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-10-01 2017-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-10-01 2017-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-10-01 2017-12-31 0000096793 2017-10-01 2017-12-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2016-10-01 2016-12-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2016-10-01 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-10-01 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-10-01 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-10-01 2016-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-10-01 2016-12-31 0000096793 ssy:PharmacySegmentMember 2016-10-01 2016-12-31 0000096793 us-gaap:ManagementMember 2016-10-01 2016-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2016-10-01 2016-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2016-10-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2016-10-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2016-10-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2016-10-01 2016-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-10-01 2016-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-10-01 2016-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-10-01 2016-12-31 0000096793 2016-10-01 2016-12-31 0000096793 2012-07-03 2014-12-31 0000096793 ssy:CarmichaelsCashwayPharmacyIncMemberus-gaap:ScenarioForecastMember 2018-01-01 2018-03-31 0000096793 us-gaap:ScenarioForecastMember 2022-01-01 2022-12-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-12-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2017-07-01 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-07-01 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2017-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-07-01 2017-12-31 0000096793 ssy:PharmacySegmentMember 2017-07-01 2017-12-31 0000096793 ssy:PharmacySegmentMemberstpr:LA 2017-07-01 2017-12-31 0000096793 us-gaap:ManagementMember 2017-07-01 2017-12-31 0000096793 ssy:NursingHomeMemberssy:HealthcareServicesSegmentMemberstpr:MS 2017-07-01 2017-12-31 0000096793 ssy:NursingHomeMemberssy:HealthcareServicesSegmentMemberstpr:GA 2017-07-01 2017-12-31 0000096793 ssy:CommunityHospitalMemberssy:HealthcareServicesSegmentMember 2017-07-01 2017-12-31 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2017-07-01 2017-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-07-01 2017-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2017-07-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2017-07-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2017-07-01 2017-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2017-07-01 2017-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2017-07-01 2017-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-07-01 2017-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2017-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-07-01 2017-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-07-01 2017-12-31 0000096793 2017-07-01 2017-12-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-12-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-12-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-12-31 0000096793 ssy:PharmacySegmentMember 2016-07-01 2016-12-31 0000096793 us-gaap:ManagementMember 2016-07-01 2016-12-31 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2016-07-01 2016-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2016-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2016-07-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2016-07-01 2016-12-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2016-07-01 2016-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-07-01 2016-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-07-01 2016-12-31 0000096793 2016-07-01 2016-12-31 0000096793 us-gaap:ScenarioForecastMember 2018-01-01 2021-12-31 0000096793 ssy:CarmichaelsCashwayPharmacyIncMemberus-gaap:SubsequentEventMember 2018-01-11 2018-01-11 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-26 2017-12-26 0000096793 ssy:CommonSharePurchaseTenderOfferMember 2017-12-21 2017-12-21 0000096793 ssy:ChestateeHospitalMemberssy:AssetPurchaseAgreementMember 2016-08-19 2016-08-19 0000096793 ssy:ChestateeHospitalMember 2016-08-19 2016-08-19 0000096793 us-gaap:ScenarioForecastMemberssy:LaterThanMember 2022-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 ssy:PharmacySegmentMember 2017-06-30 0000096793 us-gaap:ManagementMember 2017-06-30 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-06-30 0000096793 2017-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-06-30 0000096793 ssy:PharmacySegmentMember 2016-06-30 0000096793 2016-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2017-12-31 0000096793 ssy:PharmacySegmentMember 2017-12-31 0000096793 us-gaap:ManagementMember 2017-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-12-31 0000096793 ssy:ChestateeHospitalMember 2017-12-31 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2017-12-31 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2017-12-31 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2017-12-31 0000096793 ssy:OperatingLeasesMember 2017-12-31 0000096793 ssy:InterestOnOutstandingDebtMember 2017-12-31 0000096793 us-gaap:LongTermDebtMember 2017-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2017-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-12-31 0000096793 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-09-30 0000096793 ssy:PharmacySegmentMember 2017-09-30 0000096793 2017-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-12-31 0000096793 ssy:PharmacySegmentMember 2016-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-12-31 0000096793 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-09-30 0000096793 ssy:PharmacySegmentMember 2016-09-30 0000096793 2016-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-26 0000096793 ssy:CommonSharePurchaseTenderOfferMember 2017-12-21 0000096793 2018-02-14 0000096793 ssy:CommonSharePurchaseTenderOfferMember 2017-11-21 iso4217:USD shares shares pure iso4217:USD ssy:Segment ssy:Bed ssy:Services ssy:Hospital

EX-101.SCH 8 ssy-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Economic Damages Claim link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Restricted Cash link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Economic Damages Claim - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Restricted Cash - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Intangible Assets - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Subsequent Event - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 ssy-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 ssy-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 ssy-20171231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accrued Liabilities, Current Due to third party payors Accrued penalty expense. Accrued penalty expense Accrued penalties expense Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts [Table Text Block] Summary of Allowance for Doubtful Accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset purchase agreement. Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Assets Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets: Assets, Noncurrent [Abstract] Noncurrent Assets: Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Capital Lease Obligations Capital lease obligations and other Carmichael's Cashway Pharmacy, Inc. Carmichael's Cashway Pharmacy, Inc [Member] Carmichael's Cashway Pharmacy, Inc [Member] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in Cash and Cash Equivalents Chestatee hospital. Chestatee Hospital [Member] Chestatee Hospital [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common share purchase tender offer. Common Share Purchase Tender Offer [Member] Common Share Purchase Tender Offer [Member] Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 7,417 shares at December 31, 2017 and 9,163 at June 30, 2017 Community hospital. Community Hospital [Member] Community Hospital [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Earnings Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate and Other [Member] Cost of Goods Sold Cost of goods sold Cost of Services Purchased services Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Debt instrument interest rate, basis spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument Floor Interest Rate Debt Instrument Floor Interest Rate Debt instrument, interest rate floor Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment, Principal Monthly principal payment of loan Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Federal alternative minimum tax, tax credits Deferred Tax Assets, Valuation Allowance Deferred income tax valuation allowance Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Expected contribution to pension plan during the remaining fiscal year Defined Benefit Plan, Expected Return (Loss) on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Net pension expense Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on sale Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (Loss) before income taxes: Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Earnings (Loss) before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Earnings (Loss) from discontinued operations Earnings (Loss) from Discontinued Operations, net of tax Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Income tax expense Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Group Name [Domain] Disposal Group Name [Domain] Divestiture of businesses purchase price adjustment receivable. Divestiture Of Businesses Purchase Price Adjustment Receivable Purchase price adjustment due to from hospital buyer Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Earnings: Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Revenue from Financial and Health Care Services Financial And Healthcare Services Revenue Net revenues Operating revenues (net of contractual allowances) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] GEORGIA Georgia [Member] Gain (Loss) Related to Litigation Settlement Gain on economic damages claim, net Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Gain (Loss) on Disposition of Assets for Financial Service Operations Gain (Loss) on sale of assets Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Healthcare facilities segment. Healthcare Facilities Segment [Member] Healthcare Facilities Segment [Member] Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. Health Care Organization, Medicare and Medicaid Electronic Health Records Incentives, Gain (Loss) EHR incentive payments Health Care Organization, Patient Service Revenue Provision for Bad Debts Less provision for bad debts of Healthcare Facilities segment Provision for doubtful accounts Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organizations [Abstract] Health Care Organizations [Abstract] Healthcare services segment. Healthcare Services Segment [Member] Healthcare Services Segment [Member] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Earnings from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Taxes Receivable, Noncurrent Income taxes receivable Income Tax Expense (Benefit) Income Tax Benefit Income tax expense (benefit) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets - net Total Interest bearing covenant deposit. Interest Bearing Covenant Deposit Interest bearing deposit under financial covenant Interest Expense Interest expense net Interest on outstanding debt. Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid Interest Inventory, Net Inventory LOUISIANA Louisiana [Member] Labor and Related Expense Salaries, wages and benefits Later Than [Member] Later Than [Member] Later Than [Member] Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Loans Payable RDA Loan Long-term Debt Total Total Long-term Debt, Current Maturities Current maturities of long-term debt, net of debt issuance costs Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Long-term debt, net of debt issuance costs Total Long-term debt, excluding current maturities, total Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingencies [Table] Loss Contingencies [Table] Contingencies Disclosure [Text Block] Economic Damages Claim Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] Management [Member] Management [Member] Medicaid. Medicaid [Member] Medicaid [Member] Medicare license. Medicare License [Member] Medicare License [Member] Medicare. Medicare [Member] Medicare [Member] Mortgages [Member] Mortgages [Member] MISSISSIPPI Mississippi [Member] Nature of Operations [Text Block] Business Operations Net Cash Provided by (Used in) Financing Activities Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows Used in Financing Activities: Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows Provided by (Used in) Investing Activities: Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities EX-101.PRE 12 ssy-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Dec. 31, 2017	Feb. 14, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		7,416,814

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Current Assets:
Cash and cash equivalents	$ 2,959	$ 10,494
Restricted cash	0	1,000
Receivables - net	6,360	5,906
Inventory	2,149	2,159
Prepaid expense and other assets	4,058	3,062
Total current assets	15,526	22,621
Property, plant and equipment, at cost	29,673	28,609
Less accumulated depreciation	19,124	18,319
Property, plant and equipment - net	10,549	10,290
Noncurrent Assets:
Intangible assets - net	1,529	1,587
Income taxes receivable	296	0
Other noncurrent assets	758	838
Total noncurrent assets	2,583	2,425
TOTAL ASSETS	28,658	35,336
Current liabilities:
Accounts payable	1,765	1,571
Current maturities of long-term debt, net of debt issuance costs	263	6,710
Accrued payroll and related taxes	1,932	2,098
Due to third party payors	307	658
Other accrued expenses	1,171	1,277
Total current liabilities	5,438	12,314
Long-Term Liabilities
Long-term debt, net of debt issuance costs	2,929	0
Noncurrent liability for professional liability risks	829	1,040
Other noncurrent liabilities	258	289
Total long-term liabilities	4,016	1,329
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 7,417 shares at December 31, 2017 and 9,163 at June 30, 2017	3,708	4,581
Additional paid-in capital	11,038	13,103
Retained earnings	4,785	4,336
Accumulated other comprehensive loss	(327)	(327)
Total Shareholders' Equity	19,204	21,693
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 28,658	$ 35,336

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Jun. 30, 2017
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	7,417,000	9,163,000
Common shares, outstanding	7,417,000	9,163,000

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Operating revenues (net of contractual allowances)	$ 14,038	$ 14,359	$ 27,471	$ 27,438
Less provision for bad debts of Healthcare Facilities segment	160	104	230	137
Net revenues	13,878	14,255	27,241	27,301
Costs and Expenses
Cost of goods sold	5,092	5,433	9,550	10,069
Salaries, wages and benefits	5,888	5,759	11,652	11,604
Provision for bad debts of Pharmacy segment	88	125	208	216
Supplies	488	482	913	918
Purchased services	662	713	1,349	1,421
Other operating expenses	1,145	1,111	2,587	2,821
Rent and lease expense	160	138	314	267
EHR incentive payments	(4)	0	(21)	0
Depreciation and amortization	439	466	868	910
Operating Profit (Loss)	(80)	28	(179)	(925)
Other Income (Expense):
Gain (Loss) on sale of assets	(4)	2,995	(2)	3,017
Gain on economic damages claim, net	944	0	944	0
Loss on extinguishment of debt	(238)	(289)	(238)	(243)
Interest expense net	(119)	(157)	(246)	(378)
Earnings from Continuing Operations before income taxes	503	2,577	279	1,471
Income Tax Benefit	(296)	(372)	(296)	(228)
Earnings from Continuing Operations	799	2,949	575	1,699
Earnings (Loss) from Discontinued Operations, net of tax	(73)	149	(126)	4,422
Net Earnings	726	3,098	449	6,121
Other comprehensive income	0	0	0	0
Comprehensive Earnings	$ 726	$ 3,098	$ 449	$ 6,121
Continuing Operations:
Basic	$ 0.09	$ 0.31	$ 0.06	$ 0.18
Diluted	0.09	0.31	0.06	0.18
Discontinued Operations:
Basic	(0.01)	0.02	(0.01)	0.47
Diluted	(0.01)	0.02	(0.01)	0.47
Net Earnings:
Basic	0.08	0.33	0.05	0.65
Diluted	$ 0.08	$ 0.33	$ 0.05	$ 0.65
Weighted-Average Common Shares Outstanding:
Basic	8,688	9,443	9,125	9,443
Diluted	8,758	9,450	9,196	9,449

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Cash Flows [Abstract]
Net Cash Provided by (Used in) Operating Activities	$ 265	$ (3,914)
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations	(1,072)	(808)
Proceeds from sale of other assets	2	4,936
Proceeds from sale of hospital	0	14,620
Net Cash Provided by (Used in) Investing Activities	(1,070)	18,748
Cash Flows Used in Financing Activities:
Payments on long-term debt - continuing operation	(3,784)	(3,716)
Repurchase of common shares	(2,946)	0
Net Cash Used in Financing Activities	(6,730)	(3,716)
Net increase (decrease) in Cash and Cash Equivalents	(7,535)	11,118
Cash and Cash Equivalents Beginning of Period	10,494	3,261
Cash and Cash Equivalents End of Period	2,959	14,379
Cash Paid for:
Interest	218	206
Income taxes	$ 0	$ 33

XML 18 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	6 Months Ended
Basis of Presentation	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2017 and for the three and six month periods ended December 31, 2017 and 2016 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2017 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on September 28, 2017. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

XML 19 R7.htm IDEA: XBRL DOCUMENT

Business Operations	6 Months Ended
Business Operations	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Operations	Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84-bed community hospital and a 66-bed nursing home in Mississippi, a 100-bed nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets. The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines. On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $188 will be reported in results for the three months ended March 31, 2018. Throughout these notes to the consolidated financial statements, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Discontinued Operations

6 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended December 31,						Six Months Ended December 31,
	2017			2016			2017			2016
Net Revenues:
Chestatee Hospital	$	0		$	268		$	0		$	2,369
Other Sold Hospitals		6			14			(6	)		(220	)

	$	6		$	282		$	(6	)	$	2,149

Earnings (Loss) before income taxes:
Chestatee Hospital	$	(37	)	$	251		$	(38	)	$	187
Other Sold Hospitals		0			3			(16	)		(235	)
Life sciences and engineering		(36	)		(38	)		(72	)		(75	)
Gain on sale of Chestatee Hospital		0			24			0			7,270

Earnings (Loss) before income taxes		(73	)		240			(126	)		7,147

Income tax expense		0			91			0			2,725

Earnings (Loss) from discontinued operations	$	(73	)	$	149		$	(126	)	$	4,422

The components of pension expense for the three and six months ended December 31, 2017 and 2016, respectively, were as follows:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Interest Cost	$	14		$	13		$	28		$	26
Expected return on assets		(9	)		(8	)		(18	)		(16	)
Amortization of prior service cost		31			33			62			65

Net pension expense	$	36		$	38		$	72		$	75

SunLink contributed $70 to the plan in the six months ended December 31, 2017 and expects to contribute an additional $70 during the last two fiscal quarters of the fiscal year ending June 30, 2018.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Economic Damages Claim	6 Months Ended
Economic Damages Claim	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Economic Damages Claim	Note 4. – Economic Damages Claim The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the three and six months ended December 31, 2017 and as of December 31, 2017, the net settlements of $944 are included in Prepaid expense and other assets on the December 31, 2017 Condensed Consolidated Balance Sheets.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Restricted Cash	6 Months Ended
Restricted Cash	Dec. 31, 2017
Receivables [Abstract]
Restricted Cash	Note 5. – Restricted Cash Under the Fourth Amendment to the Trace RDA Loan dated January 7, 2017 (see Note 9. Long-Term Debt) a deposit of $1,000 in a blocked interest bearing account was held by the lender. Under the Fifth Amendment to the Trace RDA Loan dated December 26, 2017, the blocked account was eliminated and a prepayment was made on the Trace RDA loan.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Shareholders' Equity	6 Months Ended
Shareholders' Equity	Dec. 31, 2017
Equity [Abstract]
Shareholders' Equity	Note 6. – Shareholders’ Equity *Common Share Purchase Tender Offer* – On November 21, 2017, SunLink commenced a tender offer for the purchase of a portion of its common shares at a price of $1.60 per share (the “Offer”). The offer expired on December 21, 2017 with 3,725,656 common shares tendered. In accordance with the terms and conditions of the Offer, the Company accepted for payment a total of approximately 1,745,751 shares at a price of $1.60 per share for a total cost of approximately $2,793, excluding fees and expenses relating to the Offer. *Stock-Based Compensation* – For the three months ended December 31, 2017 and 2016, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2017 and 2016, the Company recognized $6 and $54, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 0 and 72,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2017 and 2016, respectively.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables

6 Months Ended

Dec. 31, 2017

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 7. – Revenue Recognition and Accounts Receivables

Revenues by payor were as follows for the three and six months ended December 31, 2017 and 2016:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Healthcare Facilities Segment:
Medicare	$	2,386		$	2,335		$	4,682		$	4,368
Medicaid		2,102			2,404			4,237			4,900
Self-pay		269			151			441			270
Managed Care & Other Insurance		771			657			1,485			1,377
Other		354			405			761			775

Revenues before provision for doubtful accounts		5,882			5,952			11,606			11,690
Provision for doubtful accounts		(160	)		(104	)		(230	)		(137	)

Healthcare Facilities Segment Net Revenues		5,722			5,848			11,376			11,553
Pharmacy Segment Net Revenues		8,156			8,407			15,865			15,748

Total Net Revenues	$	13,878		$	14,255		$	27,241		$	27,301

Summary information for accounts receivable is as follows:


	December 31,			June 30,
	2017			2017
Accounts receivable (net of contractual allowances)	$	6,905		$	6,458
Less allowance for doubtful accounts		(545	)		(552	)

Patient accounts receivable - net	$	6,360		$	5,906


	Healthcare
	Services			Pharmacy			Total
Three Months Ended December 31, 2017
Balance at October 1, 2017	$	308		$	192		$	500
Additions recognized as a reduction to revenues:
Continuing Operations		160			88			248
Discontinued Operations		(6	)		0			(6	)
Accounts written off, net of recoveries		(136	)		(61	)		(197	)

Balance at December 31, 2017	$	326		$	219		$	545


	Healthcare
	Services			Pharmacy			Total
Six Months Ended December 31, 2017
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		230			208			438
Discontinued Operations		6			0			6
Accounts written off, net of recoveries		(238	)		(213	)		(451	)

Balance at December 31, 2017	$	326		$	219		$	545


	Healthcare
	Services			Pharmacy			Total
Three Months Ended December 31, 2016
Balance at October 1, 2016	$	402		$	390		$	792
Additions recognized as a reduction to revenues:
Continuing Operations		104			125			229
Discontinued Operations		(15	)		0			(15	)
Accounts written off, net of recoveries		(159	)		(115	)		(274	)

Balance at December 31, 2016	$	332		$	400		$	732


	Healthcare
	Services			Pharmacy			Total
Six Months Ended December 31, 2016
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		137			216			353
Discontinued Operations		392			0			392
Accounts written off, net of recoveries		(821	)		(183	)		(1,004	)

Balance at December 31, 2016	$	332		$	400		$	732

XML 25 R13.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 8. – Intangible Assets

Intangibles consist of the following, net of amortization:


	December 31			June 30,
	2017			2017
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,363	)		(1,305	)

Net Intangibles	$	1,529		$	1,587

XML 26 R14.htm IDEA: XBRL DOCUMENT

Long-Term Debt

6 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Long-Term Debt

Note 9. –Long-Term Debt

Long-term debt consisted of the following:


	December,			June 30,
	2017			2017
Trace RDA Loan	$	3,417		$	7,191
Capital lease obligations and other		2			12

Total		3,419			7,203
Less unamortized debt issuance costs		(227	)		(493	)
Less current maturities		(263	)		(6,710	)

Long-term Debt	$	2,929		$	0

XML 27 R15.htm IDEA: XBRL DOCUMENT

Income Taxes	6 Months Ended
Income Taxes	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. – Income Taxes Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $372 ($399 federal tax benefit and $27 state tax expense) was recorded for continuing operations for the three months ended December 31, 2017 and 2016, respectively. Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $228 ($189 federal tax benefit and $39 state tax benefit) was recorded for continuing operations for the six months ended December 31, 2017 and 2016, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB”) on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available. At December 31, 2017, consistent with the above processes, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that only our federal alternative minimum tax (“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $7,921 against all other net deferred tax asset items at December 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at December 31, 2017 that $7,921of the net deferred tax assets resulting from non-AMT credit carryforwards should have full valuation allowances was the three-year cumulative pre-tax loss as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at December 31, 2017, the Company had approximately $12,700 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025. With the enactment of TCJA, Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. – Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	263	$	554	$	168
2 years		300		349		152
3 years		317		293		133
4 years		336		111		113
5+ years		2,203		13		244

	$	3,419	$	1,320	$	810

XML 29 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended
Related Party Transactions	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. - Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $125 and $175 for legal services to this law firm in the three months ended December 31, 2017 and 2016, respectively. The Company expensed an aggregate of $190 and $372 for legal services to this law firm in the six months ended December 31, 2017 and 2016, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2017 and June 30, 2017 is $116 and $38, respectively, of amounts payable to this law firm.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Subsequent Event	6 Months Ended
Subsequent Event	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Event	Note 13. - Subsequent Event On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $188 will be reported in results for the three months ended March 31, 2018.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Financial Information by Segment

6 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Financial Information by Segment

Note 14. - Financial Information by Segment


	Healthcare					Corporate
	Facilities		Pharmacy			and Other			Total
As of and for the three months ended December 31, 2017
Net revenues from external customers	$	5,722	$	8,156		$	0		$	13,878
Operating profit (loss)		61		229			(370	)		(80	)
Depreciation and amortization		160		278			1			439
Assets		14,348		10,752			3,558			28,658
Expenditures for property, plant and equipment		337		51			0			388

As of and for the three months ended December 31, 2016
Net revenues from external customers	$	5,848	$	8,407		$	0		$	14,255
Operating profit (loss)		424		5			(401	)		28
Depreciation and amortization		198		267			1			466
Assets		13,859		12,022			14,762			40,643
Expenditures for property, plant and equipment		167		397			0			564

As of and for the six months ended December 31, 2017
Net revenues from external customers	$	11,376	$	15,865		$	0		$	27,241
Operating profit (loss)		4		652			(835	)		(179	)
Depreciation and amortization		318		548			2			868
Assets		14,348		10,752			3,558			28,658
Expenditures for property, plant and equipment		813		259			0			1,072

As of and for the six months ended December 31, 2016
Net revenues from external customers	$	11,553	$	15,748		$	0		$	27,301
Operating profit (loss)		292		(187	)		(1,030	)		(925	)
Depreciation and amortization		387		521			2			910
Assets		13,859		12,022			14,762			40,643
Expenditures for property, plant and equipment		222		586			0			808

XML 32 R20.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

6 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended December 31,						Six Months Ended December 31,
	2017			2016			2017			2016
Net Revenues:
Chestatee Hospital	$	0		$	268		$	0		$	2,369
Other Sold Hospitals		6			14			(6	)		(220	)

	$	6		$	282		$	(6	)	$	2,149

Earnings (Loss) before income taxes:
Chestatee Hospital	$	(37	)	$	251		$	(38	)	$	187
Other Sold Hospitals		0			3			(16	)		(235	)
Life sciences and engineering		(36	)		(38	)		(72	)		(75	)
Gain on sale of Chestatee Hospital		0			24			0			7,270

Earnings (Loss) before income taxes		(73	)		240			(126	)		7,147

Income tax expense		0			91			0			2,725

Earnings (Loss) from discontinued operations	$	(73	)	$	149		$	(126	)	$	4,422

Components of Pension Expense

The components of pension expense for the three and six months ended December 31, 2017 and 2016, respectively, were as follows:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Interest Cost	$	14		$	13		$	28		$	26
Expected return on assets		(9	)		(8	)		(18	)		(16	)
Amortization of prior service cost		31			33			62			65

Net pension expense	$	36		$	38		$	72		$	75

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

XML 33 R21.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables (Tables)

6 Months Ended

Dec. 31, 2017

Receivables [Abstract]

Summary of Revenues

Revenues by payor were as follows for the three and six months ended December 31, 2017 and 2016:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2017			2016			2017			2016
Healthcare Facilities Segment:
Medicare	$	2,386		$	2,335		$	4,682		$	4,368
Medicaid		2,102			2,404			4,237			4,900
Self-pay		269			151			441			270
Managed Care & Other Insurance		771			657			1,485			1,377
Other		354			405			761			775

Revenues before provision for doubtful accounts		5,882			5,952			11,606			11,690
Provision for doubtful accounts		(160	)		(104	)		(230	)		(137	)

Healthcare Facilities Segment Net Revenues		5,722			5,848			11,376			11,553
Pharmacy Segment Net Revenues		8,156			8,407			15,865			15,748

Total Net Revenues	$	13,878		$	14,255		$	27,241		$	27,301

Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:


	December 31,			June 30,
	2017			2017
Accounts receivable (net of contractual allowances)	$	6,905		$	6,458
Less allowance for doubtful accounts		(545	)		(552	)

Patient accounts receivable - net	$	6,360		$	5,906

Summary of Allowance for Doubtful Accounts


	Healthcare
	Services			Pharmacy			Total
Three Months Ended December 31, 2017
Balance at October 1, 2017	$	308		$	192		$	500
Additions recognized as a reduction to revenues:
Continuing Operations		160			88			248
Discontinued Operations		(6	)		0			(6	)
Accounts written off, net of recoveries		(136	)		(61	)		(197	)

Balance at December 31, 2017	$	326		$	219		$	545


	Healthcare
	Services			Pharmacy			Total
Six Months Ended December 31, 2017
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		230			208			438
Discontinued Operations		6			0			6
Accounts written off, net of recoveries		(238	)		(213	)		(451	)

Balance at December 31, 2017	$	326		$	219		$	545


	Healthcare
	Services			Pharmacy			Total
Three Months Ended December 31, 2016
Balance at October 1, 2016	$	402		$	390		$	792
Additions recognized as a reduction to revenues:
Continuing Operations		104			125			229
Discontinued Operations		(15	)		0			(15	)
Accounts written off, net of recoveries		(159	)		(115	)		(274	)

Balance at December 31, 2016	$	332		$	400		$	732


	Healthcare
	Services			Pharmacy			Total
Six Months Ended December 31, 2016
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		137			216			353
Discontinued Operations		392			0			392
Accounts written off, net of recoveries		(821	)		(183	)		(1,004	)

Balance at December 31, 2016	$	332		$	400		$	732

XML 34 R22.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangibles consist of the following, net of amortization:


	December 31			June 30,
	2017			2017
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,363	)		(1,305	)

Net Intangibles	$	1,529		$	1,587

XML 35 R23.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

6 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:


	December,			June 30,
	2017			2017
Trace RDA Loan	$	3,417		$	7,191
Capital lease obligations and other		2			12

Total		3,419			7,203
Less unamortized debt issuance costs		(227	)		(493	)
Less current maturities		(263	)		(6,710	)

Long-term Debt	$	2,929		$	0

XML 36 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	263	$	554	$	168
2 years		300		349		152
3 years		317		293		133
4 years		336		111		113
5+ years		2,203		13		244

	$	3,419	$	1,320	$	810

XML 37 R25.htm IDEA: XBRL DOCUMENT

Financial Information by Segment (Tables)

6 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Information


	Healthcare					Corporate
	Facilities		Pharmacy			and Other			Total
As of and for the three months ended December 31, 2017
Net revenues from external customers	$	5,722	$	8,156		$	0		$	13,878
Operating profit (loss)		61		229			(370	)		(80	)
Depreciation and amortization		160		278			1			439
Assets		14,348		10,752			3,558			28,658
Expenditures for property, plant and equipment		337		51			0			388

As of and for the three months ended December 31, 2016
Net revenues from external customers	$	5,848	$	8,407		$	0		$	14,255
Operating profit (loss)		424		5			(401	)		28
Depreciation and amortization		198		267			1			466
Assets		13,859		12,022			14,762			40,643
Expenditures for property, plant and equipment		167		397			0			564

As of and for the six months ended December 31, 2017
Net revenues from external customers	$	11,376	$	15,865		$	0		$	27,241
Operating profit (loss)		4		652			(835	)		(179	)
Depreciation and amortization		318		548			2			868
Assets		14,348		10,752			3,558			28,658
Expenditures for property, plant and equipment		813		259			0			1,072

As of and for the six months ended December 31, 2016
Net revenues from external customers	$	11,553	$	15,748		$	0		$	27,301
Operating profit (loss)		292		(187	)		(1,030	)		(925	)
Depreciation and amortization		387		521			2			910
Assets		13,859		12,022			14,762			40,643
Expenditures for property, plant and equipment		222		586			0			808

XML 38 R26.htm IDEA: XBRL DOCUMENT

Business Operations - Additional Information (Detail) $ in Thousands		3 Months Ended			6 Months Ended
	Jan. 11, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) Segment Bed Services	Dec. 31, 2016 USD ($)
Business And Organization [Line Items]
Number of segments \| Segment					2
Proceeds from sale					$ 0	$ 14,620
Earnings (Loss) before income taxes			$ (73)	$ 240	$ (126)	$ 7,147
Carmichael's Cashway Pharmacy, Inc [Member] \| Scenario, Forecast [Member]
Business And Organization [Line Items]
Earnings (Loss) before income taxes		$ 188
Carmichael's Cashway Pharmacy, Inc [Member] \| Subsequent Event [Member]
Business And Organization [Line Items]
Proceeds from sale	$ 410
Pharmacy Segment [Member] \| Louisiana [Member]
Business And Organization [Line Items]
Number of material service lines \| Services					4
Healthcare Services Segment [Member] \| Community Hospital [Member]
Business And Organization [Line Items]
Number of licensed-bed owned and operated by a subsidiary \| Bed					84
Healthcare Services Segment [Member] \| Nursing Home [Member] \| Mississippi [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary \| Bed					66
Healthcare Services Segment [Member] \| Nursing Home [Member] \| Georgia [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary \| Bed					100

XML 39 R27.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Aug. 19, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		$ (73)	$ 240	$ (126)	$ 7,147
Income tax expense		0	91	0	2,725
Earnings (Loss) from discontinued operations		(73)	149	(126)	4,422
Chestatee Hospital [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	$ 7,270
Discontinued Operations, Disposed of by Sale [Member]
Net Revenues:
Net revenues		6	282	(6)	2,149
Discontinued Operations, Disposed of by Sale [Member] \| Chestatee Hospital [Member]
Net Revenues:
Net revenues		0	268	0	2,369
Earnings (Loss) before income taxes:
Gain on sale		0	24	0	7,270
Earnings (Loss) before income taxes		(37)	251	(38)	187
Discontinued Operations, Disposed of by Sale [Member] \| Other Sold Hospitals [Member]
Net Revenues:
Net revenues		6	14	(6)	(220)
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		0	3	(16)	(235)
Discontinued Operations, Disposed of by Sale [Member] \| Life Sciences and Engineering [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		$ (36)	$ (38)	$ (72)	$ (75)

XML 40 R28.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Additional Information (Detail) $ in Thousands		3 Months Ended		6 Months Ended		30 Months Ended
	Aug. 19, 2016 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2014 Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale				$ 0	$ 14,620
Earnings (Loss) before income taxes		$ (73)	$ 240	(126)	$ 7,147
Number of Hospitals Sold \| Hospital						3
Chestatee Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Earnings (Loss) before income taxes	$ 7,270
Purchase price adjustment due to from hospital buyer		339		339
Chestatee Hospital [Member] \| Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 15,000
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to pension plan				70
Expected contribution to pension plan during the remaining fiscal year		$ 70		$ 70

XML 41 R29.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Interest Cost	$ 14	$ 13	$ 28	$ 26
Expected return on assets	(9)	(8)	(18)	(16)
Amortization of prior service cost	31	33	62	65
Net pension expense	$ 36	$ 38	$ 72	$ 75

XML 42 R30.htm IDEA: XBRL DOCUMENT

Economic Damages Claim - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Loss Contingencies [Line Items]
Gain on economic damages claim, net	$ 944	$ 0	$ 944	$ 0
Pharmacy Segment [Member]
Loss Contingencies [Line Items]
Gain on economic damages claim, net	$ 944		$ 944

XML 43 R31.htm IDEA: XBRL DOCUMENT

Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 0	$ 1,000
Trace RDA Loan [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 1,000

XML 44 R32.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Dec. 21, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Nov. 21, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, amount recognized		$ 1	$ 5	$ 6	$ 54
Common Share Purchase Tender Offer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common share purchase price per share	$ 1.60					$ 1.60
Number of shares tendered	3,725,656
Number of shares purchased	1,745,751
Total cost of share purchased	$ 2,793
Share purchase program expiration date	Dec. 21, 2017
2011 Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted				0	72,000

XML 45 R33.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 14,038	$ 14,359	$ 27,471	$ 27,438
Provision for doubtful accounts	(160)	(104)	(230)	(137)
Net revenues	13,878	14,255	27,241	27,301
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	5,882	5,952	11,606	11,690
Provision for doubtful accounts	(160)	(104)	(230)	(137)
Net revenues	5,722	5,848	11,376	11,553
Healthcare Facilities Segment [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,386	2,335	4,682	4,368
Healthcare Facilities Segment [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,102	2,404	4,237	4,900
Healthcare Facilities Segment [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	269	151	441	270
Healthcare Facilities Segment [Member] \| Managed Care & Other Insurance [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	771	657	1,485	1,377
Healthcare Facilities Segment [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	354	405	761	775
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 8,156	$ 8,407	$ 15,865	$ 15,748

XML 46 R34.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 6,905		$ 6,458
Less allowance for doubtful accounts	(545)	$ (500)	(552)	$ (732)	$ (792)	$ (991)
Patient accounts receivable - net	$ 6,360		$ 5,906

XML 47 R35.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	$ 500	$ 792	$ 552	$ 991
Accounts written off, net of recoveries	(197)	(274)	(451)	(1,004)
Ending balance	545	732	545	732
Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	248	229	438	353
Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(6)	(15)	6	392
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	308	402	328	624
Accounts written off, net of recoveries	(136)	(159)	(238)	(821)
Ending balance	326	332	326	332
Healthcare Facilities Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	160	104	230	137
Healthcare Facilities Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(6)	(15)	6	392
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	192	390	224	367
Accounts written off, net of recoveries	(61)	(115)	(213)	(183)
Ending balance	219	400	219	400
Pharmacy Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	88	125	208	216
Pharmacy Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	$ 0	$ 0	$ 0	$ 0

XML 48 R36.htm IDEA: XBRL DOCUMENT

Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Indefinite-lived Intangible Assets [Line Items]
Total	$ 1,529	$ 1,587
Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	2,892	2,892
Accumulated Amortization	(1,363)	(1,305)
Total	1,529	1,587
Trade Name [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,180	1,180
Customer Relationships [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 623	$ 623

XML 49 R37.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 29	$ 35	$ 58	$ 71

XML 50 R38.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Debt Instrument [Line Items]
Capital lease obligations and other	$ 2	$ 12
Total	3,419	7,203
Total	3,419	7,203
Less unamortized debt issuance costs	(227)	(493)
Less current maturities	(263)	(6,710)
Total Long-term debt, excluding current maturities, total	2,929	0
Trace RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	$ 3,417	$ 7,191

XML 51 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) - USD ($) $ in Thousands		6 Months Ended
	Dec. 26, 2017	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Prepayment of loan		$ 3,784	$ 3,716
Trace RDA Loan [Member]
Debt Instrument [Line Items]
Debt instrument maturity period		15 years
Prepayment of loan	$ 3,548
Monthly principal payment of loan	$ 39
Debt instrument description	Prime rate plus 1% with a floor of 5.5%
Debt instrument interest rate, basis spread	1.00%
Debt instrument, interest rate floor	5.50%
Effective interest rate		5.50%
Interest bearing deposit under financial covenant		$ 1,000
Trace RDA Loan [Member] \| Mortgages [Member]
Debt Instrument [Line Items]
Loan agreement amount		$ 9,975
Date of loan agreement		Jul. 05, 2012

XML 52 R40.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	48 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
Schedule of Income Taxes [Line Items]
Income tax expense (benefit)	$ (296)	$ (372)	$ (296)	$ (228)
Federal tax expense (benefit)	(296)	(399)	(296)	(189)
State tax expense (benefit)	0	$ 27	0	$ (39)
Deferred income tax valuation allowance	7,921		7,921
Net operating loss carry-forward	$ 12,700		$ 12,700
Net operating loss carryforward expiration year			2025
Scenario, Forecast [Member]
Schedule of Income Taxes [Line Items]
Percentage of AMT credit refundable					100.00%	50.00%
Later Than [Member] \| Scenario, Forecast [Member]
Schedule of Income Taxes [Line Items]
Federal alternative minimum tax, tax credits							$ 296

XML 53 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 263
Payments due in 2 years	300
Payments due in 3 years	317
Payments due in 4 years	336
Payments due in 5+ years	2,203
Contractual obligations, commitments and contingencies	3,419
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	554
Payments due in 2 years	349
Payments due in 3 years	293
Payments due in 4 years	111
Payments due in 5+ years	13
Contractual obligations, commitments and contingencies	1,320
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	168
Payments due in 2 years	152
Payments due in 3 years	133
Payments due in 4 years	113
Payments due in 5+ years	244
Contractual obligations, commitments and contingencies	$ 810

XML 54 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	6 Months Ended
	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Accrued penalties expense	$ 170

XML 55 R43.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - Management [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017
Related Party Transaction [Line Items]
Legal services to these law firms	$ 125	$ 175	$ 190	$ 372
Amount payable to law firms	$ 116		$ 116		$ 38

XML 56 R44.htm IDEA: XBRL DOCUMENT

Subsequent Event - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
	Jan. 11, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Proceeds from sale					$ 0	$ 14,620
Earnings (Loss) before income taxes			$ (73)	$ 240	$ (126)	$ 7,147
Carmichael's Cashway Pharmacy, Inc [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Earnings (Loss) before income taxes		$ 188
Carmichael's Cashway Pharmacy, Inc [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from sale	$ 410

XML 57 R45.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2017 Segment
Segment Reporting [Abstract]
Number of segments	2

XML 58 R46.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 13,878	$ 14,255	$ 27,241	$ 27,301
Operating profit (loss)	(80)	28	(179)	(925)
Depreciation and amortization	439	466	868	910
Assets	28,658	40,643	28,658	40,643	$ 35,336
Expenditures for property, plant and equipment	388	564	1,072	808
Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,722	5,848	11,376	11,553
Operating Segments [Member] \| Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,722	5,848	11,376	11,553
Operating profit (loss)	61	424	4	292
Depreciation and amortization	160	198	318	387
Assets	14,348	13,859	14,348	13,859
Expenditures for property, plant and equipment	337	167	813	222
Operating Segments [Member] \| Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	8,156	8,407	15,865	15,748
Operating profit (loss)	229	5	652	(187)
Depreciation and amortization	278	267	548	521
Assets	10,752	12,022	10,752	12,022
Expenditures for property, plant and equipment	51	397	259	586
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	0	0	0	0
Operating profit (loss)	(370)	(401)	(835)	(1,030)
Depreciation and amortization	1	1	2	2
Assets	3,558	14,762	3,558	14,762
Expenditures for property, plant and equipment	$ 0	$ 0	$ 0	$ 0

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 156 176 1 false 38 0 false 8 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.sunlinkhealth.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation Notes 6 false false R7.htm 108 - Disclosure - Business Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Business Operations Notes 7 false false R8.htm 109 - Disclosure - Discontinued Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Discontinued Operations Notes 8 false false R9.htm 110 - Disclosure - Economic Damages Claim Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLossContingencyDisclosures Economic Damages Claim Notes 9 false false R10.htm 111 - Disclosure - Restricted Cash Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRestrictedAssetsDisclosureTextBlock Restricted Cash Notes 10 false false R11.htm 112 - Disclosure - Shareholders' Equity Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Shareholders' Equity Notes 11 false false R12.htm 113 - Disclosure - Revenue Recognition and Accounts Receivables Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock Revenue Recognition and Accounts Receivables Notes 12 false false R13.htm 114 - Disclosure - Intangible Assets Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 13 false false R14.htm 115 - Disclosure - Long-Term Debt Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-Term Debt Notes 14 false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 15 false false R16.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 16 false false R17.htm 118 - Disclosure - Related Party Transactions Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 17 false false R18.htm 119 - Disclosure - Subsequent Event Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Event Notes 18 false false R19.htm 120 - Disclosure - Financial Information by Segment Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Financial Information by Segment Notes 19 false false R20.htm 121 - Disclosure - Discontinued Operations (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlockTables Discontinued Operations (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock 20 false false R21.htm 122 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlockTables Revenue Recognition and Accounts Receivables (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock 21 false false R22.htm 123 - Disclosure - Intangible Assets (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Long-Term Debt (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Long-Term Debt (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock 23 false false R24.htm 125 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Financial Information by Segment (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Financial Information by Segment (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - Business Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureBusinessOperationsAdditionalInformation Business Operations - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperations Discontinued Operations - Schedule of Discontinued Operations (Detail) Details 27 false false R28.htm 129 - Disclosure - Discontinued Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformation Discontinued Operations - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsComponentsOfPensionExpense Discontinued Operations - Components of Pension Expense (Detail) Details 29 false false R30.htm 131 - Disclosure - Economic Damages Claim - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureEconomicDamagesClaimAdditionalInformation Economic Damages Claim - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Restricted Cash - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRestrictedCashAdditionalInformation Restricted Cash - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Shareholders' Equity - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation Shareholders' Equity - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfRevenues Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) Details 33 false false R34.htm 135 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryInformationForAccountsReceivable Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) Details 34 false false R35.htm 136 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryOfAllowanceForDoubtfulAccounts Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) Details 35 false false R36.htm 137 - Disclosure - Intangible Assets - Intangible Assets (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIntangibleAssetsIntangibleAssets Intangible Assets - Intangible Assets (Detail) Details 36 false false R37.htm 138 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSummaryOfLongTermDebt Long-Term Debt - Summary of Long-Term Debt (Detail) Details 38 false false R39.htm 140 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtTraceRDALoanAndTraceWorkingCapitalLoanAdditionalInformation Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Details http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables 39 false false R40.htm 141 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfContractualObligationsCommitmentsAndContingencies Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) Details 41 false false R42.htm 143 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 43 false false R44.htm 145 - Disclosure - Subsequent Event - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation Subsequent Event - Additional Information (Detail) Details 44 false false R45.htm 146 - Disclosure - Financial Information by Segment - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentAdditionalInformation Financial Information by Segment - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Financial Information by Segment - Segment Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentSegmentInformation Financial Information by Segment - Segment Information (Detail) Details 46 false false All Reports Book All Reports ssy-20171231.xml ssy-20171231.xsd ssy-20171231_cal.xml ssy-20171231_def.xml ssy-20171231_lab.xml ssy-20171231_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/stpr/2011-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 65 0001193125-18-045737-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-045737-xbrl.zip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�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